…competing issues (“increased risk for toxicity combined with a need for greater potency”) have led to limited progress for solid tumors. The Mackall lab recently developed a new CAR T-cell…
…claim deductions for each contribution made, providing a financial incentive to support ACGT’s mission consistently. Leveraging the power of compound giving – Just as compound interest grows your savings over…
…of how common B7H3 is in solid tumors. “The bad news is it’s also expressed on some normal tissue. So, this is a good test for this project since standard…
…story of her son Callum “Cal” Miller’s fight with a rare and aggressive type of lymphoma. In her keynote presentation, she explained how Cal first complained of headaches a few…
…glioblastoma, and the average survival is 8 months. It’s the most common primary brain tumor, has one of the poorest survival rates of any type of cancer, and is one…
…on the use of chimeric antigen receptor (CAR). We will develop a CAR that specifically kills macrophages in a tumor, while sparing macrophages in healthy tissue. We will test our…
…into the mechanisms of cellular cancer immuno-modulatory therapy that we will use to design and test novel cancer immunotherapeutic approaches. This Alliance for Cancer Gene Therapy Research Fellow is funded…
…T cell activation. Based on these findings, we now propose to engineer a dendritic cell-based cancer vaccine that has been genetically silenced for this transporter and to test the impact…
…diseases in humans. This study will test the hypothesis that SV5 mutant viruses can selectively kill advanced tumors. SV5 viruses with mutation in SH or V proteins induce apoptosis in…
Anti-angiogenesis is a way of strangulating the blood supply of a tumor, since without new blood, the tumor cannot survive. Dr. Jain’s study will test an alternative treatment using a…
…virus that enhance its ability to replicate in cells have shown further improvements in tumor killing in preclinical testing. As this therapeutic virus platform is modified to be more lethal…
…efficient distribution within tumors, compared to complexly folded large proteins. The delivery of peptides fused to a protein transduction domain with adenoviral vectors is a new approach that could find…
…of both type I interferons (IFNs) and pro-inflammatory cytokines; 2) the ability to activate both plasmacytoid dendritic cells (pDCs) and conventional DCs (cDCs); and 3) the ability to activate other…
When John Bell, PhD, and his team of bright, young scholars from around the globe go to work at the Ottawa Hospital Cancer Centre (Ottawa, ON, Canada), they come face-to-face…
“Solid tumors are complex and highly heterogenous,” says Meenakshi Hegde, MD, a pediatric oncologist who conducts translational immunotherapy research at the Baylor College of Medicine Center for Cell and Gene…
…at the molecular level. With a grant from Alliance for Cancer Gene Therapy, Dr. Chen began to organize an ambitious high-throughput screening (HTS) initiative to test thousands of CAR variants…
…First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Bristol Myers Squibb. Retrieved from: https://news.bms.com/news/corporate-financial/2024/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi–as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL/default.aspx. Accessed: 03/15/2024….
…protein receptor target for T-cell therapy. CAR T-cell therapy was tested on human and mouse models of melanoma (a skin cancer). Engineered T-cell receptor therapy was tested on human and…
…cancer – and the first for a solid tumor. Phase 3 clinical trial leads to approval The FDA approval comes on the heels of a Phase 3 trial using KIMMTRAK…
